MedTrace Logo

Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

NCT05907551 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2023-08-22

No results posted yet for this study

Summary

Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities. When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and individual susceptibility. Although these dermatological adverse events are rarely serious, they can significantly alter patients' quality of life, and may even necessitate the introduction of curative treatment.

The impact of these side effects can be mitigated by the use of dermo-cosmetic products and aesthetic solutions. However, most of this supportive care is not reimbursed by the health insurance system, representing a source of inequalities in access to healthcare for cancer patients.

Conditions

  • Neoplasms

Interventions

OTHER

Questionnaires

25-items questionnaire

Sponsors & Collaborators

  • Institut de cancérologie Strasbourg Europe

    lead OTHER

Principal Investigators

  • Nelly ETIENNE-SELLOUM, PharmD · Institut de cancérologie Strasbourg Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-25
Primary Completion
2023-10-25
Completion
2023-10-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05907551 on ClinicalTrials.gov